The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

AFA-281 is under clinical development by AfaSci and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase ...

BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

Newer evidence has suggested, however, that gabapentin may not work for all pain conditions and is associated with falls. As ...

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

The efficacy of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy has been established in several controlled clinical trials. [17,18,19] These trials ...

Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain The ... successful clinical outcomes. The Phase 1 trial, set to ...

The medication is meant to be a non-addictive alternative to opioids, and has shown in multiple clinical trials the ability ...